http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Marina Tucci Gammaro Baldavira Ferreira,Igor Braga Ribeiro,Diogo Turiani Hourneaux de Moura,Thomas R. McCarty,Alberto Machado da Ponte Neto,Galileu Ferreira Ayala Farias,Antônio Afonso de Miranda Neto 대한소화기내시경학회 2021 Clinical Endoscopy Vol.54 No.6
Background/Aims: The endoscopic management of primary sclerosing cholangitis (PSC)-associated dominant strictures remainschallenging. This systematic review and meta-analysis aimed to compare balloon dilation and stent placement in the treatment ofdominant strictures among PSC patients. Methods: Literature searches on MEDLINE, EMBASE, Cochrane CENTRAL and Lilacs/Bireme were performed for studiespublished until December 2020. Measured outcomes included clinical efficacy, stricture recurrence, cumulative recurrencefree rate,transplant rate, 5-year survival rate, and adverse events (i.e., pancreatitis, cholangitis, bleeding, perforation and death). Results: A total of 5 studies (n=467) were included. Based on pooled analyses, there were no differences in clinical efficacy (riskdifference [RD], -0.13; 95% confidence interval [CI], -0.58 to 0.33; I2=93%) or transplant rates (RD, -0.09; 95% CI, -0.19 to 0.01;I2=0%); however, the risk of occurrence of adverse events was lower with balloon dilatation than with stent placement (RD,-0.34; 95% CI, -0.45 to -0.23; I2=61%). Among the types of adverse events reported, only the rates of cholangitis/bacteremia weresignificantly lower in balloon dilation patients (RD, -0.19; 95% CI, -0.25 to -0.13; I2=51%). Conclusions: Compared to balloon dilation, stent placement for dominant strictures in PSC appeared to have higher complicationrates without significant differences in efficacy.